NASDAQ : SXTP
60 Degrees Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.31M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.31M |
| Enterprise Value | 2.43M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.52M |
| Shares Outstanding | 3.52M |
| Shares Change (YoY) | +506.60% |
| Shares Change (QoQ) | +53.78% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 15.23% |
| Float | 2.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.72 |
| Forward PS | 2.23 |
| PB Ratio | 1.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.32 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -274.33 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -332.85% |
| Return on Assets (ROA) | -127.11% |
| Return on Invested Capital (ROIC) | -207.72% |
| Return on Capital Employed (ROCE) | -321.46% |
| Weighted Average Cost of Capital (WACC) | 17.39% |
| Revenue Per Employee | $404,977 |
| Profits Per Employee | -$2.87M |
| Employee Count | 3 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 3.91 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.40 |
| 52-Week Price Change | -83.21% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 48.70 |
| Average Volume (20 Days) | 1,128,121 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 135,408 |
| Short Previous Month | 133,355 |
| Short % of Shares Out | 3.85% |
| Short % of Float | 5.54% |
| Short Ratio (days to cover) | 0.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.21M |
| Gross Profit | -2.06M |
| Operating Income | -8.61M |
| Pretax Income | -8.11M |
| Net Income | -8.62M |
| EBITDA | -8.50M |
| EBIT | -8.61M |
| Loss Per Share | -$5.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.02M |
| Total Debt | 151,179 |
| Net Cash | 871,427 |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 2.53M |
| Book Value Per Share | -2.61 |
| Working Capital | 2.13M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.77M |
| Capital Expenditures | -119,880 |
| Depreciation & Amortization | 103,073 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.89M |
| FCF Per Share | -$2.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | -169.87% |
| Operating Margin | -708.47% |
| Pretax Margin | -667.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -506.60% |
| Shareholder Yield | -506.60% |
| Earnings Yield | -575.58% |
| FCF Yield | -269.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.70 |
| Price Target Difference | 293.62% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 12.38% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -21.32 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |